151 related articles for article (PubMed ID: 23222532)
1. Treatment patterns for prostate cancer: comparison of Medicare claims data to medical record review.
Fleming ST; Hamilton AS; Sabatino SA; Kimmick GG; Wu XC; Owen JB; Huang B; Hwang W;
Med Care; 2014 Sep; 52(9):e58-64. PubMed ID: 23222532
[TBL] [Abstract][Full Text] [Related]
2. Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.
Fleming ST; Kimmick GG; Sabatino SA; Cress RD; Wu XC; Trentham-Dietz A; Huang B; Hwang W; Liff JM;
Ann Epidemiol; 2012 Nov; 22(11):807-13. PubMed ID: 22948184
[TBL] [Abstract][Full Text] [Related]
3. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment.
Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA
Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973
[TBL] [Abstract][Full Text] [Related]
4. Comparison of SEER Treatment Data With Medicare Claims.
Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
[TBL] [Abstract][Full Text] [Related]
5. Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.
Hillner BE; Tosteson TD; Tosteson AN; Wang Q; Song Y; Onega T; Hanna LG; Siegel BA
Med Care; 2013 Apr; 51(4):361-7. PubMed ID: 23481033
[TBL] [Abstract][Full Text] [Related]
6. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL
Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409
[TBL] [Abstract][Full Text] [Related]
7. Construct validity of medicare chemotherapy claims: the case of 5FU.
Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA
Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793
[TBL] [Abstract][Full Text] [Related]
8. Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study.
Goldsbury DE; Smith DP; Armstrong BK; O'Connell DL
BMC Health Serv Res; 2011 Oct; 11():253. PubMed ID: 21978077
[TBL] [Abstract][Full Text] [Related]
9. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.
Klabunde CN; Harlan LC; Warren JL
Med Care; 2006 Oct; 44(10):921-8. PubMed ID: 17001263
[TBL] [Abstract][Full Text] [Related]
10. Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
Wang K; Sheets NC; Basak R; Chen RC
Cancer; 2016 Oct; 122(19):3069-74. PubMed ID: 27352280
[TBL] [Abstract][Full Text] [Related]
11. Claims data linked to hospital registry data enhance evaluation of the quality of care of breast cancer.
Meguerditchian AN; Stewart A; Roistacher J; Watroba N; Cropp M; Edge SB
J Surg Oncol; 2010 Jun; 101(7):593-9. PubMed ID: 20461766
[TBL] [Abstract][Full Text] [Related]
12. Utility of the SEER-Medicare data to identify chemotherapy use.
Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB
Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169
[TBL] [Abstract][Full Text] [Related]
13. Studying radiation therapy using SEER-Medicare-linked data.
Virnig BA; Warren JL; Cooper GS; Klabunde CN; Schussler N; Freeman J
Med Care; 2002 Aug; 40(8 Suppl):IV-49-54. PubMed ID: 12187168
[TBL] [Abstract][Full Text] [Related]
14. Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data.
Lavery JA; Lipitz-Snyderman A; Li DG; Bach PB; Panageas KS
JCO Clin Cancer Inform; 2019 Feb; 3():1-24. PubMed ID: 30715928
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.
Kuo YF; Goodwin JS; Shahinian VB
BMC Health Serv Res; 2008 Jul; 8():146. PubMed ID: 18620606
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases.
Sathiakumar N; Delzell E; Yun H; Jooste R; Godby K; Falkson C; Yong M; Kilgore ML
Med Care; 2017 Dec; 55(12):e144-e149. PubMed ID: 29135778
[TBL] [Abstract][Full Text] [Related]
17. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer.
Onukwugha E; Yong C; Hussain A; Seal B; Mullins CD
BMC Med Res Methodol; 2014 Jan; 14():1. PubMed ID: 24383436
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims Database.
Hashibe M; Ou JY; Herget K; Bolton D; McPherson J; Hawley C; Garvin J; Doherty JA; Sweeney C
JCO Clin Cancer Inform; 2019 Oct; 3():1-10. PubMed ID: 31756128
[TBL] [Abstract][Full Text] [Related]
19. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis.
Chang SL; Liao JC; Shinghal R
J Urol; 2009 Jul; 182(1):255-60; discussion 261. PubMed ID: 19450844
[TBL] [Abstract][Full Text] [Related]
20. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.
Klabunde CN; Legler JM; Warren JL; Baldwin LM; Schrag D
Ann Epidemiol; 2007 Aug; 17(8):584-90. PubMed ID: 17531502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
